4//SEC Filing
SCICLONE PHARMACEUTICALS INC 4
Accession 0000880771-17-000056
CIK 0000880771operating
Filed
Mar 16, 8:00 PM ET
Accepted
Mar 17, 4:50 PM ET
Size
8.9 KB
Accession
0000880771-17-000056
Insider Transaction Report
Form 4
Xie Lan
VP Finance China, CFO
Transactions
- Exercise/Conversion
Common Stock
2017-03-15+1,000→ 1,000 total - Sale
Common Stock
2017-03-16$9.60/sh−1,000$9,600→ 0 total - Exercise/Conversion
Restricted Stock Unit
2017-03-15−1,000→ 19,000 totalExercise: $0.00Exp: 2026-03-15→ Common Stock (1,000 underlying)
Footnotes (4)
- [F1]The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 18, 2016.
- [F2]Granted under the Issuer's 2015 Equity Incentive Plan.
- [F3]Each restricted stock unit represents the right to receive, at settlement, one share of common stock.
- [F4]Vesting for such RSUs will occur 25% on March 15, 2017, 25% on March 15, 2018, 25% on March 15, 2019, and 25% on March 15, 2020, contingent upon the executive's continued employment.
Documents
Issuer
SCICLONE PHARMACEUTICALS INC
CIK 0000880771
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0000880771
Filing Metadata
- Form type
- 4
- Filed
- Mar 16, 8:00 PM ET
- Accepted
- Mar 17, 4:50 PM ET
- Size
- 8.9 KB